SOLO2试验中CA-125与RECIST进展在BRCA突变铂敏感复发性卵巢癌患者中的一致性
该研究基于SOLO2/ENGOT-ov21试验数据,评估了接受奥拉帕利或安慰剂维持治疗的gBRCA突变铂敏感复发性卵巢癌患者中CA-125进展与RECIST进展的一致性。结果显示CA-125进展对RECIST进展的阳性预测值高(96%),但阴性预测值仅52%,近半数无CA-125进展的患者实际已有RECIST进展,且多数CA-125仍在正常范围。结论提示应定期进行CT影像学监测,而非仅依赖CA-125。
要点
- CA-125进展对RECIST进展的PPV为96%,但NPV仅52%。
- 安慰剂组NPV更低(30%),奥拉帕利组为60%。
- 无CA-125进展但有RECIST进展者中68% CA-125在正常范围。
核心结论
- 近半数无CA-125进展的患者存在RECIST进展,且多数CA-125在正常范围。
- 对于接受或不接受奥拉帕利维持治疗的患者,应考虑定期CT影像学监测而非仅依赖CA-125。
研究设计与样本
- 研究从SOLO2/ENGOT-ov21(NCT01874353)试验中提取数据,评估CA-125与RECIST进展的一致性。
- 纳入275例患者(奥拉帕利184例,安慰剂91例),排除非RECIST进展、随机化当日进展及无重复CA-125者。
- 计算CA-125进展与RECIST进展的阴性预测值(NPV)和阳性预测值(PPV)。
主要发现
- 171例患者经研究者评估为RECIST进展。
- 80例CA-125进展患者中77例RECIST进展一致(PPV 96%,95%CI 90-99%)。
- 195例无CA-125进展患者中94例RECIST进展(NPV 52%,95%CI 45-59%)。
- 奥拉帕利组PPV 95%(84-99%),NPV 60%(52-68%);安慰剂组PPV 97%(87-100%),NPV 30%(20-44%)。
- 94例有RECIST进展但无CA-125进展的患者中,64例(68%)CA-125在正常范围。
临床怎么用
- 在gBRCA突变铂敏感复发性卵巢癌维持治疗中,CA-125进展可提示RECIST进展(PPV高),但CA-125未进展不能排除RECIST进展(NPV低)。
- 建议将定期CT影像学监测作为随访的一部分,尤其对于CA-125正常或无进展的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Limited evidence exists to support CA-125 as a valid surrogate biomarker for progression in patients with ovarian cancer on maintenance PARP inhibitor (PARPi) therapy. We aimed to assess the concordance between CA-125 and Response Evaluation Criteria in Solid Tumours (RECIST) criteria for progression in patients with BRCA mutations on maintenance PARPi or placebo. METHODS: We extracted data on progression as defined by Gynecologic Cancer InterGroup CA-125, investigator- and independent central-assessed RECIST from the SOLO2/ENGOT-ov21(NCT01874353) trial. We excluded those with progression other than by RECIST, progression on date of randomisation, and no repeat CA-125 beyond baseline. We evaluated the concordance between CA-125 progression and RECIST progression, and assessed the negative (NPV) and positive predictive value (PPV). RESULTS: Of 295 randomised patients, 275 (184 olaparib, 91 placebo) were included. 171 patients had investigator-assessed RECIST progression. Of 80 patients with CA-125 progression, 77 had concordant RECIST progression (PPV 96%, 95% confidence interval 90-99%). Of 195 patients without CA-125 progression, 94 had RECIST progression (NPV 52%, 45-59%). Within treatment arms, PPV was similar (olaparib: 95% [84-99%], placebo: 97% [87-100%]) but NPV was lower in patients on placebo (olaparib: 60% [52-68%], placebo: 30% [20-44%]). Of 94 patients with RECIST but without CA-125 progression, 64 (68%) had CA-125 that remained within normal range. We observed similar findings using independent-assessed RECIST. CONCLUSIONS: Almost half the patients without CA-125 progression had RECIST progression, and most of these had CA-125 within the normal range. Regular computed tomography imaging should be considered as part of surveillance in patients treated with or without maintenance olaparib rather than relying on CA-125 alone.
引用
- Tjokrowidjaja A, Lee CK, Friedlander M, et al. Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy. Eur J Cancer. 2020. PMID: 32977221. doi:10.1016/j.ejca.2020.08.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。